Newsletter September 2019

Read the September edition of the Endo-ERN newsletter now! The Launch of the call for members to join existing 24 ERNs has opened, Endo-ERN was present at ESPE2019 and much more.
Click here for the newsletter.

Esta entrada foi publicada em Geral.

CPMS Webinar: CPMS upcoming changes

On the 24th of October, a CPMS Webinar will be held at 14:00 CET 

The topic of the Webinar is CPMS upcoming changes.

Sumário Event

EventCPMS upcoming changes
DataOutubro 24th, 2019
RegistoO registo está encerrado

Disorders of phosphate imbalance: a dysregulation of the FGF23 endocrine system

The National Coordinators of EndoERN, BondERN and ERKnet strongly aimed for this multidisciplinary meeting which brings together national and international experts on hypophosphatemia XLH to discuss its management and for its greater dissemination.

Sumário Event

Eventa dysregulation of the FGF23 endocrine system
Data8 Outubro - Outubro 8th, 2019
LocalizaçãoPadua
WebsiteVisite o site event
RegistoO registo está encerrado

July & August newsletter

The July & August-edition of the Endo-ERN newsletter is out now! The call for new members to join the ERN will launch soon, 11 new Affiliated Partners joined the European Reference Network, information about the upcoming events and much more!

Click here for the newsletter

Esta entrada foi publicada em Geral.

Wolfram syndrome scientific and family meeting in Cardano al Campo (Varese, Italy)

On behalf of the “Associazione Gentian” the “Wolfram Syndrome Italy Association” we cordially invite you to the national scientific and family meeting to be held in Cardano al Campo (Varese, Italy), 21 September 2019. The meeting brings together Italian scientists, families and patients and will be focused on Wolfram syndrome. You will have the unique opportunity to network with colleagues and experts in the field.

Please click here for the program.

 

Medical treatment for MCT8 deficiency

Background Deficiency of the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) causes severe intellectual and motor disability and high serum tri-iodothyronine (T3) concentrations (Allan–Herndon–Dudley syndrome). This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected individuals to substantial morbidity and mortality. Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the T3 analogue Triac (3,3′,5-tri-iodothyroacetic acid, or tiratricol), in patients with MCT8 deficiency.

Continuar a ler

Esta entrada foi publicada em MTG8.